Company
Teva Pharmaceuticals
739 Legal Matters
164
141
434
Teva Pharmaceuticals Company IP News and Updates
Mikele Bicolli
•
Mikele Bicolli
•
Mar 1, 2024
Shares of UroGen Pharma (NASDAQ: URGN) took a minor premarket hit following news that Teva Pharmaceutical (NYSE: TEVA) has submitted...
Mikele Bicolli
•
Mikele Bicolli
•
Jan 2, 2024
Corcept Therapeutics experienced a significant drop in its stock value by 27% on Tuesday following an unfavorable verdict in...
Pedram Sameni
•
Pedram Sameni
•
Nov 9, 2023
In August, our much-anticipated fourth annual ANDA Litigation Intelligence Report made its entrance into the world of pharmaceutical litigation. This...
Mikele Bicolli
•
Mikele Bicolli
•
Sep 28, 2023
In a groundbreaking legal development, Eli Lilly has secured a remarkable victory in a high-stakes patent battle that...
Pedram Sameni
•
Pedram Sameni
•
Sep 29, 2022
Last August, we published our third annual ANDA Litigation Intelligence Report. The report covered the ANDA litigation landscape and focused...
Pedram Sameni
•
Pedram Sameni
•
Sep 22, 2022
Last month, we released our third annual ANDA Litigation Intelligence Report evaluating all stakeholders in ANDA/Hatch-Waxman cases filed over the...
scott eads
•
scott eads
•
Oct 6, 2020
CASE OF THE WEEK GlaxoSmithKline LLC v. Teva Pharmaceuticals USA, Inc., Appeal No. 2018-1976, -2023 (Fed. Cir. Oct. 2, 2020)...
Knobbe Martens
•
Knobbe Martens
•
Oct 5, 2020
GLAXOSMITHKLINE LLC v. TEVA PHARMACEUTICALS USA, INC. [OPINION] – PRECEDENTIAL Before Prost, Newman, and Moore. Appeal from the U.S. District...
Warren Woessner
•
Warren Woessner
•
Mar 6, 2020
In Galderma Labs. v. Teva Pharm. USA, Inc., Appeal Nos. 2019-2396 and 2020-1213 (Fed. Cir,. January 29, 2020), a Fed....
Warren Woessner
•
Warren Woessner
•
May 17, 2019
Last year, in a lengthy split decision, a Fed. Cir. panel affirmed the district court’s ruling that four “add-on” patents...
Showing 1-10 of 14 news found